Back to News
Market Impact: 0.3

This Quantum Computing Stock Is Poised for a Sharp Selloff in the Second Half of 2026

Technology & InnovationCompany FundamentalsBanking & LiquidityDilution (Capital Structure/Equity Issuance)Investor Sentiment & Positioning

Rigetti’s full-year 2025 revenue was about $7M, down 34% YoY, while its market capitalization remains in the billions—implying a price-to-sales in the hundreds versus peers trading far lower. The company also faces ongoing dilution, having raised roughly $100M via an ATM program and accepted about $100M in 2026 federal quantum funding that included a government equity stake, both of which expand the share count. The article argues the stock already prices in years of quantum success, leaving limited downside protection if hype cools.

Analysis

This is less a near-term fundamental short than a capital-structure story: when a pre-revenue-ish name can fund growth by issuing stock into momentum, the stock becomes a financing vehicle first and a business second. That usually keeps downside contained for a while, but it also creates a persistent supply overhang that can cap any rally once incremental buyers are exhausted. The key second-order effect is that each financing round pushes the required future operating performance higher, so the burden of proof compounds faster than the product roadmap. For the peer set, the market is likely to discriminate more sharply after this. IONQ should hold up better on relative grounds because revenue traction gives it a cleaner path to justify dilution, while QBTS is more exposed to a sentiment unwind because it lacks the same “validation” narrative and already trades on future optionality. If this tape weakens, expect the first-order selloff to hit the highest-duration names, but the second-order effect is multiple compression across the whole quantum basket as investors reassess how much funding these companies will need before meaningful commercialization. The contrarian point is that the real risk is not immediate insolvency; it is the opposite—too much funding, too much time, and too much equity issuance. That makes the short thesis vulnerable to sharp squeezes on any technical milestone or government-related announcement, so timing matters more than direction. The thesis is falsified if RGTI shows two consecutive quarters of accelerating revenue or if dilution slows materially; absent that, the path of least resistance over the next 1-3 months is lower once enthusiasm fades.